原发性肝癌患者血浆循环核酸p53基因突变情况探讨  

p53 gene mutation research in Primary liver cancer patients with cycle nucleic acid

作　　者：许吉一[1] 张柏秋[2] 于海龙[3] 

机构地区：[1]长春市中心血站,吉林长春130033 [2]长春市中心医院介入科 [3]大连医科大学检验医学院

出　　处：《中国实验诊断学》2009年第12期1722-1725,共4页Chinese Journal of Laboratory Diagnosis

摘　　要：目的了解原发性肝癌患者血浆循环核酸p53基因突变情况,探讨其临床意义。方法提取57例原发性肝癌患者和40例乙型肝炎患者血浆循环核酸,应用聚合酶链反应(PCR)方法扩增p53基因5-8外显子,用单链构象多态性(SSCP)方法检测其突变情况。结果检出原发性肝癌患者p53基因突变率为40.3%,显著高于对照组乙型肝炎的5%,二者存在显著差异(χ2=15.35,P<0.05)。结论p53基因突变可能是肝细胞癌的病因之一,聚合酶链反应-单链构象多态性方法可以作为肝癌诊断一种辅助手段,为基因治疗的开展提供依据。Objective To study plasma nucleic acid p53 gene mutation status and its clinical significance in human hepatocellular carcinoma（HCC）.Methods extract cycle nucleic acid,the polymerase chain reaction-single strand conformation more State analysis（PCR-SSCP） detected 57 cases of patients with primary liver cancer and 40 cases of patients with hepatitis B p53 gene exon 5-8 of the mutation.Results p53 gene in patients with primary liver cancer the mutation detection rate of 40.3 percent,significantly higher than 5% of the hepatitis.Conclusion p53 gene mutation in patients with primary liver cancer in a higher detection rate,as in the diagnosis of liver cancer a aid for gene therapy to provide a basis to carry out.

关 键 词：原发性肝癌 P53基因 DNA突变分析 聚合酶链反应 

分 类 号：R735.7[医药卫生—肿瘤]